Each vial contains 250/500 mg (potency) amikacin as the sulfate.
Amikacin sulfate, a semi-synthetic aminoglycoside antibiotic derived from kanamycin has a broad spectrum of antibacterial activity.
Amikacin sulfate resists degradation by most aminoglycoside-inactivating enzymes known to affect gentamicin, tobramycin and kanamycin.
Amikacin sulfate is active in vitro against penicillinase and non-penicillinase producing Staphylococcus species, including methicillin-resistant strains.
Amikacin sulfate combined with a β-lactam antibiotic acts synergistically against many clinically significant Gram-negative organisms.